[go: up one dir, main page]

NO20013340D0 - Antagonister for TWEAK og for TWEAK-reseptor samt anvendelse derav ved behandling av immunologiske lidelser - Google Patents

Antagonister for TWEAK og for TWEAK-reseptor samt anvendelse derav ved behandling av immunologiske lidelser

Info

Publication number
NO20013340D0
NO20013340D0 NO20013340A NO20013340A NO20013340D0 NO 20013340 D0 NO20013340 D0 NO 20013340D0 NO 20013340 A NO20013340 A NO 20013340A NO 20013340 A NO20013340 A NO 20013340A NO 20013340 D0 NO20013340 D0 NO 20013340D0
Authority
NO
Norway
Prior art keywords
tweak
antagonists
treatment
immunological disorders
receptor
Prior art date
Application number
NO20013340A
Other languages
English (en)
Other versions
NO20013340L (no
Inventor
Paul Rennert
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO20013340D0 publication Critical patent/NO20013340D0/no
Publication of NO20013340L publication Critical patent/NO20013340L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
NO20013340A 1999-01-15 2001-07-05 Antagonister for TWEAK og for TWEAK-reseptor samt anvendelse derav ved behandling av immunologiske lidelser NO20013340L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11616899P 1999-01-15 1999-01-15
PCT/US2000/001044 WO2000042073A1 (en) 1999-01-15 2000-01-14 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders

Publications (2)

Publication Number Publication Date
NO20013340D0 true NO20013340D0 (no) 2001-07-05
NO20013340L NO20013340L (no) 2001-09-17

Family

ID=22365656

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013340A NO20013340L (no) 1999-01-15 2001-07-05 Antagonister for TWEAK og for TWEAK-reseptor samt anvendelse derav ved behandling av immunologiske lidelser

Country Status (21)

Country Link
US (5) US20020015703A1 (no)
EP (1) EP1141027A1 (no)
JP (3) JP5550799B2 (no)
KR (1) KR20010102978A (no)
CN (1) CN1387538A (no)
AU (1) AU2507700A (no)
BR (1) BR0007556A (no)
CA (1) CA2358684C (no)
CZ (1) CZ20012548A3 (no)
EA (1) EA004590B1 (no)
EE (1) EE200100372A (no)
HK (1) HK1038755A1 (no)
HU (1) HUP0105044A3 (no)
IL (1) IL144007A0 (no)
IS (1) IS5986A (no)
MX (1) MXPA01007163A (no)
NO (1) NO20013340L (no)
NZ (1) NZ529355A (no)
SK (1) SK10042001A3 (no)
TR (1) TR200102021T2 (no)
WO (1) WO2000042073A1 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US7001992B2 (en) * 1997-05-30 2006-02-21 Human Genome Sciences, Inc. Antibodies to secreted protein HEMCM42
EE200100372A (et) * 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
AU782067B2 (en) * 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
CA2408228A1 (en) * 2000-05-08 2001-11-15 Biogen, Inc. Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
JP2004508415A (ja) * 2000-09-14 2004-03-18 バイオジェン　インコーポレイテッド 抗脈管形成因子としてのｔｗｅａｋレセプターアゴニスト
EP1997512B1 (en) * 2002-04-09 2013-12-04 Biogen Idec MA Inc. Methods for treating TWEAK-related conditions
EP1558640B1 (en) 2002-10-29 2011-04-13 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
ES2287773T3 (es) 2003-07-24 2007-12-16 Amgen Inc. Composiciones y metodos relacionados con fragmentos solubles multimericos y oligomericos del receptor tweak.
CA2536086C (en) * 2003-08-20 2013-03-19 University Of Miami Inhibition of dr3 in the treatment of allergic lung inflammation
EP1566636A1 (en) * 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
WO2006052926A2 (en) * 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006088890A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
DK2332408T3 (da) * 2005-02-17 2013-12-02 Biogen Idec Inc Behandling af neurologiske sygdomme
ZA200707489B (en) * 2005-03-07 2008-12-31 Genentech Inc Methods and compositions for modulating tweak and FN14 activity
ES2432564T3 (es) * 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
DK1888113T3 (da) * 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
AU2013200995B2 (en) * 2005-05-27 2016-08-04 Biogen Ma Inc. Tweak binding antibodies
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20070128184A1 (en) 2005-08-30 2007-06-07 Eckhard Podack Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
US20100284933A1 (en) * 2006-10-16 2010-11-11 Biogen Idec Ma Inc. Biomarkers of Multiple Sclerosis
US9056908B2 (en) 2007-08-03 2015-06-16 Abbvie Biotherapeutics Inc. Therapeutic use of anti-tweak receptor antibodies
WO2010003108A2 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS
CA2729810A1 (en) * 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tgf-.beta. antagonist multi-target binding proteins
US20130124426A1 (en) * 2008-10-02 2013-05-16 ecoATM, Inc. Method And Apparatus For Recycling Electronic Devices
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
SG10201502330TA (en) 2009-08-03 2015-05-28 Univ Miami Method for in vivo expansion of t regulatory cells
WO2011097500A2 (en) 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
PH12013500506A1 (en) * 2010-10-05 2017-08-23 Hoffmann La Roche Antibodies against human tweak and uses thereof
AU2012225246B2 (en) 2011-03-10 2016-01-21 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
US9456755B2 (en) 2011-04-29 2016-10-04 Medtronic, Inc. Method and device to monitor patients with kidney disease
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
CA2897826C (en) 2013-01-09 2022-09-27 Taylor H. Schreiber Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
EP3019874B1 (en) * 2013-07-09 2019-08-21 The Translational Genomics Research Institute Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14
US9797882B2 (en) 2013-07-09 2017-10-24 The Translational Genomics Research Institute Method of screening for a compound for inhibitory activity of FN14-tweak interaction
JP2017029001A (ja) * 2013-12-19 2017-02-09 国立研究開発法人産業技術総合研究所 プロテインｇの細胞膜外ドメインの新規な改変型タンパク質
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
WO2017131972A1 (en) * 2016-01-25 2017-08-03 Oxytec Llc Soil and water remediation method and apparatus for treatment of recalcitrant halogenated substances
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11661360B2 (en) 2020-06-18 2023-05-30 Wp&E Technologies And Solutions, Llc System for removing per- and polyfluorinated alkyl substances from contaminated aqueous streams, via chemical aided filtration, and methods of use thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200313A (en) 1983-08-05 1993-04-06 Miles Inc. Nucleic acid hybridization assay employing detectable anti-hybrid antibodies
US4921698A (en) 1984-05-25 1990-05-01 Asahi Kasei Kogyo Kabushiki Kaisha Polypeptide having gamma-interferon activity lacking amino acids coded by exon 4
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AT396939B (de) 1990-05-29 1993-12-27 Alois Dipl Ing Dr Jungbauer Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0679716A4 (en) 1993-11-12 1999-06-09 Kenichi Matsubara GENE SIGNATURE.
WO2001053486A1 (en) 1999-03-08 2001-07-26 Genentech, Inc. Compositions and methods for the treatment of tumor
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
AU708829B2 (en) 1994-12-13 1999-08-12 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
US6544761B2 (en) 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
CN1308451C (zh) * 1996-08-07 2007-04-04 拜奥根Idec马萨诸塞公司 肿瘤坏死因子相关配基
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US5858991A (en) 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
JP2001513626A (ja) 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1998055508A2 (en) 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
ES2306480T3 (es) 1997-09-18 2008-11-01 Genentech, Inc. Polipeptido dcr3, un homologo de tnfr.
CA2305713A1 (en) * 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
US20020072089A1 (en) 1999-11-23 2002-06-13 Holtzman Douglas A. Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor
US6046381A (en) 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
WO1999059614A1 (en) 1998-05-20 1999-11-25 Yale University Modulation of angiogenesis and wound healing
WO1999061471A2 (en) 1998-05-29 1999-12-02 Incyte Pharmaceuticals, Inc. Human transmembrane proteins
WO2000023094A2 (en) 1998-10-16 2000-04-27 Immunex Corporation Methods of inhibiting platelet activation and recruitment
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
ATE353339T1 (de) 1998-12-22 2007-02-15 Genentech Inc Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums
EE200100372A (et) * 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
KR20050004240A (ko) 1999-08-31 2005-01-12 제넨테크, 인크. 종양 치료용 조성물 및 방법
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
US6727225B2 (en) * 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
JP4723782B2 (ja) 2000-01-03 2011-07-13 ティーアール アソシエイツ，エル．エル．シー． 新規なキメラ蛋白質及び該蛋白質の使用方法
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
AU2001247219B2 (en) 2000-02-25 2007-01-04 Immunex Corporation Integrin antagonists
CA2408228A1 (en) * 2000-05-08 2001-11-15 Biogen, Inc. Method for promoting neovascularization
US20040047854A1 (en) 2001-07-27 2004-03-11 Black Roy A. Human disintegrin protein
JP2004508415A (ja) 2000-09-14 2004-03-18 バイオジェン　インコーポレイテッド 抗脈管形成因子としてのｔｗｅａｋレセプターアゴニスト
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
WO2002053737A1 (fr) 2000-12-28 2002-07-11 Asahi Kasei Kabushiki Kaisha Gene d'activation de nf-kb
EP1381622A2 (en) 2001-03-21 2004-01-21 Human Genome Sciences, Inc. Human secreted proteins
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US6756101B2 (en) 2001-07-16 2004-06-29 Specialty Tapes, Division Of Rsw Tape for use with high-speed webs and method of use thereof
US20040091473A1 (en) 2001-07-27 2004-05-13 Dubose Robert F. Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
AU2002363354A1 (en) 2001-07-27 2003-05-19 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
US20030148314A1 (en) 2001-08-01 2003-08-07 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US20040033495A1 (en) 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
EP1997512B1 (en) 2002-04-09 2013-12-04 Biogen Idec MA Inc. Methods for treating TWEAK-related conditions
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
EP1599607A2 (en) 2003-03-04 2005-11-30 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
ES2287773T3 (es) * 2003-07-24 2007-12-16 Amgen Inc. Composiciones y metodos relacionados con fragmentos solubles multimericos y oligomericos del receptor tweak.
EP1566636A1 (en) 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
WO2006052926A2 (en) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
DK2332408T3 (da) 2005-02-17 2013-12-02 Biogen Idec Inc Behandling af neurologiske sygdomme
ZA200707489B (en) * 2005-03-07 2008-12-31 Genentech Inc Methods and compositions for modulating tweak and FN14 activity
ES2432564T3 (es) * 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
DK1888113T3 (da) 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20100284933A1 (en) * 2006-10-16 2010-11-11 Biogen Idec Ma Inc. Biomarkers of Multiple Sclerosis
EP2294089A2 (en) * 2008-05-15 2011-03-16 Biogen Idec MA Inc. Anti-fn14 antibodies and uses thereof
WO2010085648A2 (en) 2009-01-23 2010-07-29 Linda Burkly C Methods for reducing radiation-induced tissue damage
KR20110117690A (ko) 2009-01-30 2011-10-27 비오겐 아이덱 엠에이 아이엔씨. 췌장 조직 재생 방법
PH12013500506A1 (en) * 2010-10-05 2017-08-23 Hoffmann La Roche Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
JP2010275320A (ja) 2010-12-09
JP2004500320A (ja) 2004-01-08
US20020015703A1 (en) 2002-02-07
SK10042001A3 (sk) 2001-12-03
EE200100372A (et) 2002-10-15
JP5550799B2 (ja) 2014-07-16
US20100061985A1 (en) 2010-03-11
IS5986A (is) 2001-06-29
CA2358684A1 (en) 2000-07-20
BR0007556A (pt) 2001-10-23
IL144007A0 (en) 2002-04-21
CZ20012548A3 (cs) 2001-10-17
JP5592195B2 (ja) 2014-09-17
JP2013075916A (ja) 2013-04-25
KR20010102978A (ko) 2001-11-17
US20070110745A1 (en) 2007-05-17
EA200100780A1 (ru) 2001-12-24
US20120027751A1 (en) 2012-02-02
NZ529355A (en) 2005-05-27
CN1387538A (zh) 2002-12-25
HUP0105044A3 (en) 2004-07-28
MXPA01007163A (es) 2002-03-27
US20050008636A1 (en) 2005-01-13
HK1038755A1 (zh) 2002-03-28
US7169387B2 (en) 2007-01-30
US8440189B2 (en) 2013-05-14
US7579001B2 (en) 2009-08-25
EA004590B1 (ru) 2004-06-24
AU2507700A (en) 2000-08-01
CA2358684C (en) 2013-07-16
EP1141027A1 (en) 2001-10-10
WO2000042073A1 (en) 2000-07-20
NO20013340L (no) 2001-09-17
HUP0105044A2 (hu) 2002-04-29
TR200102021T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
NO20013340L (no) Antagonister for TWEAK og for TWEAK-reseptor samt anvendelse derav ved behandling av immunologiske lidelser
NO20014524L (no) Rekombinant IL-18 antagonister anvendelige i behandling av IL- 18 medierte forstyrrelser
GB9927056D0 (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
IS5113A (is) Notkun antagónista CB1-viðtaka til meðhöndlunar löngunartruflana
NO20001754L (no) Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
HUE039348T2 (hu) A2A receptor antagonisták mozgási rendellenességek kezelésében történõ alkalmazásra
NO996483L (no) Imidasopyrimidiner og imidasopyridiner for behandling av neurologiske lidelser
IL174593A0 (en) NOVEL TETRAHYDROSPIRO{PIPERIDINE-2,7'-PYRROLO[3,2-b]PYRIDINE} DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS
NO20022680L (no) Farmasoytiske kombinasjoner og deres anvendelse ved behandling av gastrointestinale forstyrrelser
ATE235467T1 (de) Antagonisten des vitronectin-rezeptors
NO20032636D0 (no) 3-indolinderivater som er nyttige i behandlingen av psykiatriske og nevrologiske forstyrrelser
IL145301A0 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders
NO20034232D0 (no) Anvendelse av glukokortikoid-reseptor-spesifikke antagonister ved behandling av stresslidelser
HUP0202048A3 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
EP0747055A3 (en) Use of tachykinin receptor antagonists to treat the common cold and allergic rhinitis
HUP0202339A3 (en) Use of cortisol antagonists in the treatment of heat failure
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
PL351554A1 (en) Osanetant in the treatment of mood disorders
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
IL157102A0 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
GB2353471B (en) Composition for treating obesity and related disorders and using therof
IL160551A0 (en) Plaster for the treatment of dysfunctions and disorders of nails
GB9911178D0 (en) Agents useful in the treatment of reproductive disorders
IS5718A (is) Notkun alfa1ß1 integrín viðtaka hindra og TGF-ß1 hindra í meðferð nýrnasjúkdóma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application